SCHEMBL6019203

SCHEMBL6019203

CNCC1CCC(C(=O)NC)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.42
GSK3B P49841 1/20 0.39
VCP P55072 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CHRNB2 P17787 2/20 0.38
CHRNA4 P43681 2/20 0.38
CHRNA7 P36544 1/20 0.38
LMNA P02545 2/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
KDM1A O60341 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
TP53 P04637 1/20 0.36
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8253098 1.00 EPHX1 (0.42) EPHX1GSK3BVCPTDP1CHRNB2
SCHEMBL8255737 0.84 EPHX1 (0.40) EPHX1GSK3BVCPTDP1CHRNB2
SCHEMBL13018829 0.82 EPHX1 (0.47) EPHX1GSK3BVCPTDP1CHRNB2
SCHEMBL463737 0.82 EPHX1 (0.47) EPHX1GSK3BVCPTDP1CHRNB2
SCHEMBL103880 0.82
SCHEMBL5909567 0.82 CHRNB2 (0.50) CHRNB2CHRNA4CHRNA7LMNACHRNB4
SCHEMBL20032107 0.81 EPHX1 (0.42) EPHX1GSK3BVCPTDP1CHRNB2
SCHEMBL20077541 0.81 CHRNB2 (0.39) EPHX1GSK3BVCPCHRNB2CHRNA4
SCHEMBL12118171 0.81 TDP1 (0.40) EPHX1TDP1LMNAKDM1ACYP1A2
SCHEMBL15200263 0.81 ALDH1A1 (0.40) EPHX1GSK3BCHRNB2CHRNA4CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456171-B1 SUBSTITUTED CYCLOHEXANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-12-20 EP claimed
US-20230338568-A1 NOVEL ISOMERIC COMPOUNDS COMPRISING A RING-OPENED THIOSUCCINIMIDE GROUP, AN OLIGOPEPTIDE FRAGMENT AND A CHIRAL MOIETY GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) 2023-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338568-A1 NOVEL ISOMERIC COMPOUNDS COMPRISING A RING-OPENED THIOSUCCINIMIDE GROUP, AN OLIGOPEPTIDE FRAGMENT AND A CHIRAL MOIETY ANPEP, DNPEP, RNPEP EPHX1 3922/4885GSK3B 4360/4885VCP 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.